全文获取类型
收费全文 | 1434篇 |
免费 | 78篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 31篇 |
妇产科学 | 204篇 |
基础医学 | 164篇 |
口腔科学 | 33篇 |
临床医学 | 218篇 |
内科学 | 180篇 |
皮肤病学 | 11篇 |
神经病学 | 38篇 |
特种医学 | 108篇 |
外科学 | 208篇 |
综合类 | 39篇 |
一般理论 | 1篇 |
预防医学 | 106篇 |
眼科学 | 1篇 |
药学 | 55篇 |
中国医学 | 2篇 |
肿瘤学 | 120篇 |
出版年
2019年 | 13篇 |
2018年 | 16篇 |
2015年 | 15篇 |
2014年 | 14篇 |
2013年 | 28篇 |
2012年 | 40篇 |
2011年 | 43篇 |
2010年 | 23篇 |
2009年 | 30篇 |
2008年 | 38篇 |
2007年 | 53篇 |
2006年 | 60篇 |
2005年 | 38篇 |
2004年 | 41篇 |
2003年 | 62篇 |
2002年 | 38篇 |
2001年 | 46篇 |
2000年 | 55篇 |
1999年 | 38篇 |
1998年 | 27篇 |
1997年 | 20篇 |
1996年 | 27篇 |
1995年 | 21篇 |
1994年 | 34篇 |
1993年 | 28篇 |
1992年 | 40篇 |
1991年 | 49篇 |
1990年 | 42篇 |
1989年 | 37篇 |
1988年 | 37篇 |
1987年 | 42篇 |
1986年 | 35篇 |
1985年 | 28篇 |
1984年 | 18篇 |
1983年 | 23篇 |
1982年 | 11篇 |
1981年 | 20篇 |
1980年 | 13篇 |
1979年 | 16篇 |
1978年 | 18篇 |
1977年 | 24篇 |
1976年 | 23篇 |
1975年 | 25篇 |
1974年 | 28篇 |
1973年 | 20篇 |
1972年 | 12篇 |
1971年 | 11篇 |
1970年 | 15篇 |
1969年 | 12篇 |
1968年 | 14篇 |
排序方式: 共有1521条查询结果,搜索用时 171 毫秒
31.
32.
Lilian A Inocencio Anderson A Pereira Maria Cecilia A Sucupira Jos Carlos C Fernandez Clia P Jorge Denise FC Souza Helena T Fink Ricardo S Diaz Irina M Becker Theodoro A Suffert Monica B Arruda Olinda Macedo Mariangela BG Simo Amilcar Tanuri 《Journal of the International AIDS Society》2009,12(1):20-20
33.
34.
Increased expression of the G gamma and A gamma globin genes associated with a mutation in the A gamma enhancer 总被引:1,自引:0,他引:1
Balta G; Brickner HE; Takegawa S; Kazazian HH Jr; Papayannopoulou T; Forget BG; Atweh GF 《Blood》1994,83(12):3727-3737
We have previously described a unique type of delta beta-thalassemia in a Chinese family characterized by increased expression of the G gamma and A gamma fetal globin genes in the absence of a large deletion in the beta-globlin gene cluster. Our earlier study of the beta-globin gene on this delta beta-thalassemia chromosome showed a promoter mutation in the TATA box. In this report, we describe the results of our study of the fetal globin domain of this delta beta-thalassemia chromosome. We have cloned a 13-kb DNA fragment that includes the G gamma and the A gamma genes and the 3' A gamma enhancer element of this delta beta-thalassemia chromosome. DNA sequence analysis of the G gamma and A gamma-globin genes including their promoters did not show any mutations, but analysis of the putative enhancer element downstream from the A gamma-globin gene showed a C to T substitution 2,401 nucleotides downstream from the A gamma cap site. We performed DNA linkage analysis to determine if this mutation is unique to this chromosome or represents a common polymorphism. Our linkage analysis showed that this mutation is not a common polymorphism and that it is also not an intrinsic part of the haplotype of the chromosome on which it was found. We also studied the interaction of nuclear proteins from erythroid and nonerythroid cells with the DNA sequences surrounding this mutation. We have shown by in vitro DNase I footprinting that this mutation falls within a region that is occupied by a novel DNA-binding protein that binds to this site in nuclear extracts from erythroid, but not nonerythroid cells. The binding of this nuclear protein to DNA appears to be dependent on GATA-1 binding to an adjacent GATA-1 site. We have also developed a new functional assay to compare the activity of the normal and mutant A gamma enhancer elements in erythroid cells. Analysis of the activity of the mutant enhancer shows that the mutation completely eliminates all enhancer activity in this assay. These findings suggest that this mutation of the A gamma enhancer on a chromosome that carries a partially inactivated beta-globin gene may be responsible for the increased expression of both gamma-globin genes seen in this condition. 相似文献
35.
CALLA-positive myeloma: an aggressive subtype with poor survival 总被引:5,自引:0,他引:5
Detailed immunotyping was carried out on 21 direct myeloma bone marrow aspirates and eight human myeloma cell lines. Four previously untreated common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma patients were identified and six of eight cell lines (75%) were also positive. CALLA positivity, as part of an immature B phenotype, was found to correlate with very aggressive clinical disease: median survival six months v 56 months for the CALLA-negative group. 相似文献
36.
W.L. Marsh N.J. Marsh A. Moore W.A. Symmans C.L. Johnson and C.M. Redman 《Vox sanguinis》1981,40(6):403-411
Abstract. McLeod phenotype red cells of the Kell blood group system have acanthocytic morphology and reduced in vivo survival. The phenotype has an X-linked mode of inheritance and is found in some males who have no abnormality of leukocyte function and in some who have X-linked chronic granulomatous disease (CGD). We now describe an association between the McLeod phenotype and an abnormal elevation of serum creatine phosphokinase (CPK). The increase is of the MM isoenzyme type, derived from skeletal muscle or cardiac muscle, and muscle biopsy shows evidence of muscle cell changes. All of 11 males who have McLeod syndrome but do not have CGD have high levels of serum CPK. Males with McLeod syndrome and CGD may have normal or high levels of the enzyme. Individuals with other variant phenotypes in the Kell system have normal levels of serum CPK. Studies on a large kindred, which includes 5 people of McLeod phenotype, show high CPK levels only in the members of McLeod type. We conclude that the high level of CPK in the serum of these people is a reflection of a muscle cell anomaly and that in these individuals it is a pleiotropic effect of the X-linked gene that produces the McLeod red cell phenotype. 相似文献
37.
Hereditary elliptocytosis (HE) is a heterogeneous disorder of red blood cells frequently associated with abnormal limited tryptic digestion of the alpha I domain of spectrin and impaired spectrin dimer self- association. We studied two related individuals with poikilocytic hereditary elliptocytosis (HE) of different severity. Limited tryptic digestion of spectrin from these individuals showed the presence of a variant alpha I/50b Kd peptide at the expense of the normal alpha I/80 Kd peptide. Amino acid sequence analysis of the abnormal peptide showed that the proteolytic cleavage occurred after the arginine at position 470 of the alpha spectrin chain. Spectrin from these patients had an impaired ability to undergo self-association, as evidenced by increased amounts of spectrin dimers in 4 degrees C extracts of erythrocyte membrane from affected individuals. The polymerase chain reaction was used to study the DNA sequence of the alpha spectrin gene encoding the region of the alpha spectrin chain surrounding the abnormal proteolytic cleavage site. We detected the in-frame deletion of the trinucleotide CAT, encoding histidine 469, two amino acid residues to the N-terminal side of the abnormal proteolytic cleavage site between residues 470 and 471. Similar to many other defects of spectrin associated with HE, this deletion occurs in helix three of repeat 5 of the proposed triple helical model of spectrin repeats. 相似文献
38.
Keating MJ; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich EJ; McCredie KB 《Blood》1989,74(1):19-25
Fludarabine was used to treat 68 patients with previously treated chronic lymphocytic leukemia (CLL). Nine (13%) patients achieved a complete remission and 30 (44%) a partial remission. The response rates for Rai stages 0 to 2, 3, and 4 were 64%, 58%, and 50% respectively. Seventeen (43%) of the 40 Rai stage 1 to 3 patients and four (19%) of the Rai stage 4 patients returned to Rai stage 0. Survival was strongly correlated with the final Rai stage achieved. The survival of the 11 partial responders with residual disease consisting only of residual bone-marrow nodules was similar to the complete responders (36+ months) and superior to the other partial response patients (16 months). The response to fludarabine was rapid, with 36 (92%) of the 39 responders having achieved at least a partial response following the first three courses. Complete responses occurred in the blood, liver, spleen, and lymph nodes in 48% to 69% of the patients. Eradication of all disease in the bone marrow occurred in only 13% of the cases. Neutropenia and thrombocytopenia occurred in 56% and 25% of evaluable courses. Major infections occurred in 9% of evaluable courses and fevers of unknown origin or minor infections in 12% of courses respectively. Myelosuppression and infection were more common in patients with initial Rai stages 3 and 4 and in nonresponding patients. Other toxicity was mild. No CNS toxicity was noted. 相似文献
39.
Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity 总被引:1,自引:0,他引:1
Pasarica M Zachwieja JJ Dejonge L Redman S Smith SR 《The Journal of clinical endocrinology and metabolism》2007,92(11):4265-4270
RATIONALE: GH replacement in GH-deficient adults results in an improvement in metabolic status. GH might also decrease visceral adiposity in obese adults that are not GH deficient. OBJECTIVE: Our objective was to determine the effects of supraphysiological GH therapy on the metabolic syndrome and visceral adiposity in men with low blood levels of IGF-I and the durability of these effects after stopping GH therapy. DESIGN: The study was a double-blind, placebo-controlled 6-month intervention trial followed by a blinded follow-up period of 6 months. SUBJECTS: Thirty nondiabetic middle-aged men with central adiposity (body mass index > 27 kg/m(2); waist circumference > 102 cm) participated. RESULTS: After 6 months of GH therapy, we observed an increase in weight and lean body mass (2.5 +/- 0.6 kg, P < 0.05 compared with baseline and placebo) and 8.8% reduction in visceral adiposity. GH increased resting energy expenditure by 172.5 +/- 41.6 kcal/24 h after 6 months of therapy. Fasting insulin, glucose, and the quantitative insulin sensitivity check index for insulin resistance increased during GH therapy. The effects of GH on fatness and visceral adiposity disappeared shortly after GH withdrawal, but weight remained increased over baseline and when compared with the placebo group (P < 0.05). CONCLUSION: These data suggest that GH therapy is associated with small but statistically significant decreases in visceral adiposity and an increase in lean mass and body weight. In viscerally obese subjects, supraphysiological GH administration is not an effective treatment; however, additional studies are needed to evaluate the effects of low-dose, physiological GH treatment. 相似文献
40.